Focus Partners Wealth’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History
Bought
Maintained
Sold
Other funds holding XPH
KWM
FCBT
Focus Partners Wealth's XPH Position: Q1 2026 in Review
Focus Partners Wealth reduced its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 7.3% in Q1 2026, selling an estimated $19.2K and leaving 4,389 shares worth $237K. The position accounts for ﹤0.01% of the portfolio, ranked #2310.
Focus Partners Wealth first reported a position in XPH in Q4 2025 and has held it in 2 quarters since. The position peaked at $265K in Q4 2025. 82 funds tracked by Wall St. Rank hold XPH as of Q1 2026.
- Focus Partners Wealth held 4,389 shares of State Street SPDR S&P Pharmaceuticals ETF worth $237K as of Q1 2026.
- Focus Partners Wealth sold 345 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2026, an estimated $19.2K.
- State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #2310 holding.
- Focus Partners Wealth first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2025 and has held it in 2 quarters since.
- Focus Partners Wealth's State Street SPDR S&P Pharmaceuticals ETF position peaked at $265K in Q4 2025.
- 82 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2026.
Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.